A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Placebo in Lung Diseases and Bronchitis, Chronic, sponsored by Bayer. Completed at 78 sites in 15 countries. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-10-28.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.
Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 6th largest by enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2004, is one of 19 in phase 3, and was the 25th registered.
209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.
Browse Bronchitis, Chronic studies →7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Austria and 15 more countries
Ages 40–75
UCB Biopharma SRL · Sites in United States, China
Ages 40–80
Rush University Medical Center · Sites in United States
Ages 40+
Freenome Holdings Inc. · Sites in United States
Ages 50+
COPD Foundation · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 45 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 25 · Phase 3 19 · Phase 4 15
First in 1994; this study’s year is marked. 6 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,404 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.
Median enrollment 126 across the 82 interventional studies, 1,429 across the 18 observational. Of the 78 that completed or were terminated, 33 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 100 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 6 studies filed under Bronchitis, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Bronchitis, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06981078Upstream Bio Inc.A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 100 studies in Bronchitis, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of chronic bronchitis he has. Approximately 1132 subjects will participate, and it is expected that the study will run for 2 years in order to reach that goal. The patients individual involvement in the study will be 17 months. Moxifloxacin will be compared to a placebo drug (no active ingredients). The study medication (moxifloxacin or placebo) will be taken in addition to the patients normal medication for chronic bronchitis. In addition to the first clinic visit, called a screening visit, the patient will be required to come back to the clinic for ten more study visits, every 8 weeks. At the first visit the study co-ordinator will provide him with the dates for all the visits. Over a period of 48 weeks the patient will return to the clinic on 6 occasions where he will receive the study medication which he will take for five days, in addition to his normal treatment for chronic bronchitis. After this time the patient will enter a follow up period for 24 weeks, where he will come to the clinic for assessments and continue to take his normal medication but not receive the study drug. A complete medical history will be taken at the first visit, including the patients past and current smoking habit. A breath test will be performed to assess how well his lungs are functioning. In addition, he will also be asked to provide a sputum sample for a microbiological examination to identify any bacteria present in the sample. The patient must be able to provide a sputum sample at the screening visit. If the patient meets all the inclusion / exclusion criteria for the study, he will be allocated randomly to one of the following treatment groups at the second visit.- Treatment group 1: Receives moxifloxacin orally once daily for five days.- Treatment group 2: Receives a matching placebo once daily for five days.In between each visit (four weeks after your clinic visit), the study site co-ordinator will contact the patient to check on his well being. If the patient or the doctor decides to stop the patients participation in the trial for any reason, the patient will be required to return to the clinic for a physical examination, take a breath test, provide a sputum sample (if possible) and have a blood sample taken.
209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.
This study's enrollment of 1,404 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.
Browse Bronchitis, Chronic studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Compared within Bronchitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Avelox (Moxifloxacin, BAY12-8039)
Drug: Placebo
Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
Matching placebo capsules orally once daily for 5 days every 8 weeks.
Number of exacerbations after 48 weeks of intermittent pulse treatment
Time frame: After 48 weeks of treatment
Impact of treatment on the health related Quality of Life in St. George's Respiratory Questionaire (SGRQ) scores
Time frame: At week 48
Deterioration in lung function test (PFEV1)
Time frame: At week 48
Frequency of hospitalisation
Time frame: At week 48
Mortality rates
Time frame: At week 48
Time of first exacerbation
Time frame: Through to week 48
Frequency of acute exacerbation of chronic bronchitis
Time frame: At week 24 and 72 (end of follow-up)
Time to next exacerbation from last pulsed dose
Time frame: At week 48
Length of exacerbations
Time frame: Through to week 48
Percentage of exacerbation free time
Time frame: Through to week 48
The record gives a start of Oct 2004, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin